Tokyo Tape
Sign in
← PHC Holdings

Quarterly report · Q2

6523.TEDINET S100PICM
Period2022-04-01 → 2022-09-30
Filed2022-11-09
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 61
MetricValuePeriodScopeSource row
Revenue¥170.6bn2022-04-01 → 2022-09-30Cons.Revenue IFRS
Revenue¥89.1bn2022-07-01 → 2022-09-30dCons.Revenue IFRS
Revenue¥340.5bn2021-04-01 → 2022-03-31Cons.Revenue IFRS (5-year summary)
Revenue¥166.1bn2021-04-01 → 2021-09-30Cons.Revenue IFRS
Revenue¥85.1bn2021-07-01 → 2021-09-30dCons.Revenue IFRS
Operating income¥10.5bn2022-04-01 → 2022-09-30Cons.Operating profit loss IFRS
Operating income¥8.5bn2022-07-01 → 2022-09-30dCons.Operating profit loss IFRS
Operating income¥13.5bn2021-04-01 → 2021-09-30Cons.Operating profit loss IFRS
Operating income¥7.9bn2021-07-01 → 2021-09-30dCons.Operating profit loss IFRS
Profit before tax¥3.4bn2022-04-01 → 2022-09-30Cons.Profit loss before tax IFRS
Profit before tax¥9.7bn2022-07-01 → 2022-09-30dCons.Profit loss before tax IFRS
Profit before tax¥3.0bn2021-04-01 → 2022-03-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥20.1bn2021-04-01 → 2021-09-30Cons.Profit loss before tax IFRS
Profit before tax¥6.0bn2021-07-01 → 2021-09-30dCons.Profit loss before tax IFRS
Net income (owners)¥1.2bn2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥8.3bn2022-07-01 → 2022-09-30dCons.Profit loss attributable to owners of parent IFRS
Net income (owners)−¥8.5bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥15.0bn2021-04-01 → 2021-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥4.6bn2021-07-01 → 2021-09-30dCons.Profit loss attributable to owners of parent IFRS
Net income¥1.4bn2022-04-01 → 2022-09-30Cons.Profit loss IFRS
Net income¥8.5bn2022-07-01 → 2022-09-30dCons.Profit loss IFRS
Net income¥15.1bn2021-04-01 → 2021-09-30Cons.Profit loss IFRS
Net income¥4.6bn2021-07-01 → 2021-09-30dCons.Profit loss IFRS
Total assets¥596.3bnat 2022-09-30Cons.Assets IFRS
Total assets¥591.3bnat 2022-03-31Cons.Assets IFRS
Total assets¥569.2bnat 2021-09-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥446.9bnat 2022-09-30Cons.Liabilities IFRS
Total liabilities¥455.3bnat 2022-03-31Cons.Liabilities IFRS
Net assets / equity¥149.3bnat 2022-09-30Cons.Equity IFRS
Net assets / equity¥136.1bnat 2022-03-31Cons.Equity IFRS
Net assets / equity¥124.1bnat 2021-09-30Cons.Equity IFRS
Net assets / equity¥107.6bnat 2021-03-31dCons.Equity IFRS
Equity (owners)¥148.3bnat 2022-09-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥135.4bnat 2022-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥123.5bnat 2021-09-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥73.7bnat 2022-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥95.2bnat 2022-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥59.6bnat 2021-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥60.8bnat 2021-03-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥5.5bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥51.1bn2021-04-01 → 2022-03-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥20.3bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥8.4bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥12.5bn2021-04-01 → 2022-03-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥6.8bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥20.6bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥7.0bn2021-04-01 → 2022-03-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥14.8bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥9.612022-04-01 → 2022-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥66.62022-07-01 → 2022-09-30dCons.Basic earnings loss per share IFRS
EPS (basic)¥-70.782021-04-01 → 2022-03-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥129.062021-04-01 → 2021-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥39.672021-07-01 → 2021-09-30dCons.Basic earnings loss per share IFRS
EPS (diluted)¥9.522022-04-01 → 2022-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥65.982022-07-01 → 2022-09-30dCons.Diluted earnings loss per share IFRS
EPS (diluted)¥-70.782021-04-01 → 2022-03-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥125.012021-04-01 → 2021-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥38.422021-07-01 → 2021-09-30dCons.Diluted earnings loss per share IFRS
Equity ratio24.9%at 2022-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio22.9%at 2022-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio21.7%at 2021-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 30
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-09-30¥1.1bn
Reconciling Itemsreconcilingrevenue external2022-04-01 → 2022-09-30¥1.1bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-09-30−¥9.4bn
jpcrp040300-q2r_E36976-000Diabetes Managementreportable segmentrevenue2022-04-01 → 2022-09-30¥55.4bn
jpcrp040300-q2r_E36976-000Diabetes Managementreportable segmentrevenue external2022-04-01 → 2022-09-30¥55.4bn
jpcrp040300-q2r_E36976-000Diabetes Managementreportable segmentsegment profit2022-04-01 → 2022-09-30¥12.0bn
jpcrp040300-q2r_E36976-000Diagnostics And Life Sciencesreportable segmentrevenue2022-04-01 → 2022-09-30¥49.3bn
jpcrp040300-q2r_E36976-000Diagnostics And Life Sciencesreportable segmentrevenue external2022-04-01 → 2022-09-30¥49.3bn
jpcrp040300-q2r_E36976-000Diagnostics And Life Sciencesreportable segmentsegment profit2022-04-01 → 2022-09-30¥2.7bn
jpcrp040300-q2r_E36976-000Healthcare Solutionsreportable segmentrevenue2022-04-01 → 2022-09-30¥64.8bn
jpcrp040300-q2r_E36976-000Healthcare Solutionsreportable segmentrevenue external2022-04-01 → 2022-09-30¥64.8bn
jpcrp040300-q2r_E36976-000Healthcare Solutionsreportable segmentsegment profit2022-04-01 → 2022-09-30¥5.3bn
—segment totalrevenue2022-04-01 → 2022-09-30¥169.5bn
—segment totalrevenue external2022-04-01 → 2022-09-30¥169.5bn
—segment totalsegment profit2022-04-01 → 2022-09-30¥20.0bn
Reconciling Itemsreconcilingrevenue2021-04-01 → 2021-09-30¥1.4bn
Reconciling Itemsreconcilingrevenue external2021-04-01 → 2021-09-30¥1.4bn
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-09-30−¥8.8bn
jpcrp040300-q2r_E36976-000Diabetes Managementreportable segmentrevenue2021-04-01 → 2021-09-30¥53.7bn
jpcrp040300-q2r_E36976-000Diabetes Managementreportable segmentrevenue external2021-04-01 → 2021-09-30¥53.7bn
jpcrp040300-q2r_E36976-000Diabetes Managementreportable segmentsegment profit2021-04-01 → 2021-09-30¥10.5bn
jpcrp040300-q2r_E36976-000Diagnostics And Life Sciencesreportable segmentrevenue2021-04-01 → 2021-09-30¥44.0bn
jpcrp040300-q2r_E36976-000Diagnostics And Life Sciencesreportable segmentrevenue external2021-04-01 → 2021-09-30¥44.0bn
jpcrp040300-q2r_E36976-000Diagnostics And Life Sciencesreportable segmentsegment profit2021-04-01 → 2021-09-30¥3.0bn
jpcrp040300-q2r_E36976-000Healthcare Solutionsreportable segmentrevenue2021-04-01 → 2021-09-30¥66.9bn
jpcrp040300-q2r_E36976-000Healthcare Solutionsreportable segmentrevenue external2021-04-01 → 2021-09-30¥66.9bn
jpcrp040300-q2r_E36976-000Healthcare Solutionsreportable segmentsegment profit2021-04-01 → 2021-09-30¥8.8bn
—segment totalrevenue2021-04-01 → 2021-09-30¥164.6bn
—segment totalrevenue external2021-04-01 → 2021-09-30¥164.6bn
—segment totalsegment profit2021-04-01 → 2021-09-30¥22.3bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 976
ItemContextValueUnit
Intersegment revenue IFRSPrior1YTDDuration－JPY
Revenue IFRSPrior1YTDDuration_jpcrp040300-q2r_E36976-000DiabetesManagementReportableSegmentMember53734000000JPY
Revenue IFRSPrior1YTDDuration_jpcrp040300-q2r_E36976-000HealthcareSolutionsReportableSegmentMember66869000000JPY
Revenue IFRSPrior1YTDDuration_jpcrp040300-q2r_E36976-000DiagnosticsAndLifeSciencesReportableSegmentMember44037000000JPY
Revenue IFRSPrior1YTDDuration_ReportableSegmentsMember164641000000JPY
Revenue IFRSPrior1YTDDuration_ReconcilingItemsMember1409000000JPY
Revenue IFRSPrior1YTDDuration166051000000JPY
Operating profit loss IFRSPrior1YTDDuration_jpcrp040300-q2r_E36976-000DiabetesManagementReportableSegmentMember10494000000JPY
Operating profit loss IFRSPrior1YTDDuration_jpcrp040300-q2r_E36976-000HealthcareSolutionsReportableSegmentMember8825000000JPY
Operating profit loss IFRSPrior1YTDDuration_jpcrp040300-q2r_E36976-000DiagnosticsAndLifeSciencesReportableSegmentMember3004000000JPY
Operating profit loss IFRSPrior1YTDDuration_ReportableSegmentsMember22324000000JPY
Operating profit loss IFRSPrior1YTDDuration_ReconcilingItemsMember-8783000000JPY
Operating profit loss IFRSPrior1YTDDuration13541000000JPY
Finance income IFRSPrior1YTDDuration7789000000JPY
Finance costs IFRSPrior1YTDDuration1182000000JPY
Profit loss before tax IFRSPrior1YTDDuration20148000000JPY
Depreciation and amortization operating expenses IFRSPrior1YTDDuration_jpcrp040300-q2r_E36976-000DiabetesManagementReportableSegmentMember6797000000JPY
Depreciation and amortization operating expenses IFRSPrior1YTDDuration_jpcrp040300-q2r_E36976-000HealthcareSolutionsReportableSegmentMember5215000000JPY
Depreciation and amortization operating expenses IFRSPrior1YTDDuration_jpcrp040300-q2r_E36976-000DiagnosticsAndLifeSciencesReportableSegmentMember3327000000JPY
Depreciation and amortization operating expenses IFRSPrior1YTDDuration_ReportableSegmentsMember15340000000JPY
Depreciation and amortization operating expenses IFRSPrior1YTDDuration_ReconcilingItemsMember316000000JPY
Depreciation and amortization operating expenses IFRSPrior1YTDDuration15656000000JPY
Impairment losses pl IFRSPrior1YTDDuration_jpcrp040300-q2r_E36976-000DiabetesManagementReportableSegmentMember6000000JPY
Impairment losses pl IFRSPrior1YTDDuration_jpcrp040300-q2r_E36976-000HealthcareSolutionsReportableSegmentMember－JPY
Impairment losses pl IFRSPrior1YTDDuration_jpcrp040300-q2r_E36976-000DiagnosticsAndLifeSciencesReportableSegmentMember-90000000JPY
Impairment losses pl IFRSPrior1YTDDuration_ReportableSegmentsMember-83000000JPY
Impairment losses pl IFRSPrior1YTDDuration_ReconcilingItemsMember－JPY
Impairment losses pl IFRSPrior1YTDDuration-83000000JPY
Revenue from external customers IFRSCurrentYTDDuration_jpcrp040300-q2r_E36976-000DiabetesManagementReportableSegmentMember55401000000JPY
Revenue from external customers IFRSCurrentYTDDuration_jpcrp040300-q2r_E36976-000HealthcareSolutionsReportableSegmentMember64825000000JPY
Revenue from external customers IFRSCurrentYTDDuration_jpcrp040300-q2r_E36976-000DiagnosticsAndLifeSciencesReportableSegmentMember49295000000JPY
Revenue from external customers IFRSCurrentYTDDuration_ReportableSegmentsMember169522000000JPY
Revenue from external customers IFRSCurrentYTDDuration_ReconcilingItemsMember1062000000JPY
Revenue from external customers IFRSCurrentYTDDuration170584000000JPY
Intersegment revenue IFRSCurrentYTDDuration_jpcrp040300-q2r_E36976-000DiabetesManagementReportableSegmentMember－JPY
Intersegment revenue IFRSCurrentYTDDuration_jpcrp040300-q2r_E36976-000HealthcareSolutionsReportableSegmentMember－JPY
Intersegment revenue IFRSCurrentYTDDuration_jpcrp040300-q2r_E36976-000DiagnosticsAndLifeSciencesReportableSegmentMember－JPY
Intersegment revenue IFRSCurrentYTDDuration_ReportableSegmentsMember－JPY
Intersegment revenue IFRSCurrentYTDDuration_ReconcilingItemsMember－JPY
Intersegment revenue IFRSCurrentYTDDuration－JPY
Revenue IFRSCurrentYTDDuration_jpcrp040300-q2r_E36976-000DiabetesManagementReportableSegmentMember55401000000JPY
Revenue IFRSCurrentYTDDuration_jpcrp040300-q2r_E36976-000HealthcareSolutionsReportableSegmentMember64825000000JPY
Revenue IFRSCurrentYTDDuration_jpcrp040300-q2r_E36976-000DiagnosticsAndLifeSciencesReportableSegmentMember49295000000JPY
Revenue IFRSCurrentYTDDuration_ReportableSegmentsMember169522000000JPY
Revenue IFRSCurrentYTDDuration_ReconcilingItemsMember1062000000JPY
Revenue IFRSCurrentYTDDuration170584000000JPY
Operating profit loss IFRSCurrentYTDDuration_jpcrp040300-q2r_E36976-000DiabetesManagementReportableSegmentMember12013000000JPY
Operating profit loss IFRSCurrentYTDDuration_jpcrp040300-q2r_E36976-000HealthcareSolutionsReportableSegmentMember5250000000JPY
Operating profit loss IFRSCurrentYTDDuration_jpcrp040300-q2r_E36976-000DiagnosticsAndLifeSciencesReportableSegmentMember2719000000JPY
Operating profit loss IFRSCurrentYTDDuration_ReportableSegmentsMember19983000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 16 of 16 passed
balance sheet identityconsolidated 2022-03-31pass
balance sheet identityconsolidated 2022-09-30pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-09-30pass
statement vs summary · net income attributable to parentconsolidated 2021-07-01/2021-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-07-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2021-04-01/2021-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2021-04-01/2021-09-30pass
statement vs summary · revenueconsolidated 2021-07-01/2021-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2022-07-01/2022-09-30pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-09-30pass